Evenity Injection

Evenity Injection works by inhibiting Sclerostin, a protein that naturally limits bone formation. By blocking this protein, Evenity signals the body to rapidly create new, high-quality bone while simultaneously reducing the rate at which old bone is broken down. This "dual effect" leads to a dramatic increase in bone mineral density (BMD) within just one year, significantly lowering the risk of spine and hip fractures.

Why Evenity is a Breakthrough in Osteoporosis

• Rapid Bone Growth: Significantly increases bone density in the lumbar spine and hip in just 12 months.

• Superior Fracture Prevention: Clinical trials show a 73% reduction in the risk of new vertebral fractures compared to placebo after one year.

• Fixed-Term Therapy: A convenient 12-month treatment course, after which patients typically transition to a maintenance therapy like Prolia (Denosumab).

• Targeted for High-Risk: Specifically designed for women who have already experienced a fracture or have failed other treatments like bisphosphonates.

Clinical Administration & Storage Guidelines

1. Full Dose Requirement: One monthly dose is 210 mg, which requires two separate 105 mg injections given one after the other.

2. Injection Sites: Subcutaneous injection in the abdomen, thigh, or upper arm. Sites should be rotated monthly.

3. Mandatory Refrigeration: Must be stored at 2°C to 8°C (36°F to 46°F).

4. Handling: Take the syringes out of the fridge 30 minutes before injection to reach room temperature (do not warm in other ways). Do not shake or freeze.